25 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Astex Therapeutics
29
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Astex Therapeutics
85
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
Astex Therapeutics
130
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
Astex Therapeutics
312
Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
Astex Therapeutics
20
Imidazole derivatives and their use as modulators of cyclin dependent kinases
Astex Therapeutics
13
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Astex Therapeutics
30
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
Astex Therapeutics
12
Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design.
Astex Therapeutics
12
Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery.
Astex Therapeutics
5
Application of fragment screening by X-ray crystallography to beta-secretase.
Astex Therapeutics
11
Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.
Astex Therapeutics
2
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
Astex Therapeutics